Clinical Trial Update: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B. [Phase 4]

View source ↗

Summary

Phase 4 study of PEGASYS (peginterferon alfa-2a) in HBeAg-positive chronic hepatitis B has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis B, Chronic | Phase 4 | Status: COMPLETED | Results posted: 2016-01-25